Vinay Prasad has stepped down as head of the FDA's Center for Biologics Evaluation and Research (CBER), less than three months after taking on the role. His departure – first reported by STAT and now ...
Top priorities at the FDA in the coming years will include shorter review timelines for drug development, embracing the use of artificial intelligence and big data, and speeding up approvals for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback